Guayaquil, Ecuador — Recently, the VitaFlow Liberty^TM Transcatheter Aortic Valve and Retrievable Delivery System ("VitaFlow Liberty^TM"), independently developed by MicroPort CardioFlow Medtech Corporation (02160.HK, "MicroPort CardioFlow"), successfully completed the first two commercial clinical applications in Ecuador. To date, the product has successfully entered several markets in Latin America, with its commercial footprint spanning nearly 40 countries and regions worldwide.

The procedures were successfully performed at the Semedic University Hospital (Hospital Universitario Semedic), a renowned private hospital in Ecuador, led by Prof. Marcos Ortega and Prof. Marcelo Medrano from the hospital, and carried out with the dedicated guidance and strong support of international expert in structural heart disease, Prof. Pablo Charry from Hospital Medilaser Neiva, Colombia.

Postoperative evaluations showed that both patients with severe aortic valve stenosis experienced no significant paravalvular leakage or other complications, marking a complete success for both procedures.

Case Details

Case 01
01 Preoperative CT Assessment
The patient was an 85-year-old male. CT analysis revealed severe aortic valve stenosis, with moderate leaflet calcification. Annulus circumference was 65.3 mm (mean diameter: 20.8 mm), LVOT circumference was 70.8 mm (mean diameter: 22.5 mm), and sinus widths were 24.3 mm / 24.8 mm / 27.0 mm.

02 Procedure Outcome
Based on a comprehensive assessment of the anatomical conditions and annular dimensions, the operator selected a VitaFlow Liberty^TM 24 mm valve. The procedure was smooth, with stable valve deployment and precise positioning. No significant complications occurred during or after the procedure.

Case 02
01 Preoperative CT Assessment
The patient was a 75-year-old male. CT analysis revealed severe aortic valve stenosis, with moderate leaflet calcification. Annulus circumference was 80.2 mm (mean diameter: 25.5 mm), LVOT circumference was 85.9 mm (mean diameter: 27.4 mm), and sinus widths were 23.6 mm / 21.7 mm / 22.2 mm.

02 Procedure Outcome
Based on the anatomical structure, annular dimensions, and coronary risk assessment, a VitaFlow Liberty^TM 27 mm valve was selected. The valve implantation process was controllable, with smooth intraoperative execution. Immediate post-procedure hemodynamics were favorable, with no significant paravalvular leakage observed.

03 Expert Evaluation
Prof. Pablo Charry commented:
"Both procedures were successfully completed without complications, fully confirming the appropriateness of the device selection and the excellent clinical performance of the VitaFlow Liberty^TM. This initiative has deepened our collaboration with the local medical team and further strengthened our confidence in the VitaFlow Liberty^TM product and technology, laying the foundation for future interventional therapy business in the region."

Prof. Marcos Ortega and Prof. Marcelo Medrano remarked:
"The procedures were highly successful, and both patients are recovering well. We look forward to more international collaboration in the future to jointly promote the advanced technology of the VitaFlow Liberty^TM, benefiting a vast number of patients."

04 Conclusion
Situated at the heart of the Andean Community, Ecuador, with its continuously developing private healthcare system, has become an important regional medical hub along the Pacific coast of South America. This first commercial clinical application not only represents another successful instance of medical technology cooperation between China and Ecuador but also signifies a further enhancement of the product's brand recognition in mainstream Latin American markets.

Moving forward, MicroPort CardioFlow will further expand deep collaboration with global medical institutions and experts at home and abroad, striving to provide more patients with innovative, comprehensive device solutions covering the full etiology, full stage, and full process of heart failure care.